Clinical Trial Update: Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sofosbuvir with pegylated interferon and ribavirin for 12 weeks in treatment-experienced chronic hepatitis C genotype 2 or 3 patients; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegylated interferon alfa-2a (Peginterferon alfa-2a)
• Ribavirin (ribavirin)
• Sofosbuvir (sofosbuvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2014-09-12